Teva announced the registration of Cinqaero, a unique innovative drug to treat severe, uncontrolled, eosinophilic asthma in adults.
The Ministry of Health of the Russian Federation decided to register the drug in accordance with its registration dossier, which also includes information on clinical trials involving placebo-controlled trials in patients aged 12-75 years old with severe, uncontrolled, bronchial asthma and blood eosinophilia.
Commenting on the registration and market launch of the innovative drug, Rustam Galeev, the Medical Director of Teva Russia & Eurasia, said: “Reslizumab is a unique drug needed by patients suffering from severe asthma that cannot be controlled by standard anti-asthma therapies. In clinical trials, it demonstrated its efficacy by reducing the number of asthma attacks, improving pulmonary function and quality of life indicators associated with the symptoms of that disease. The launch of Cinqaero® onto the Russian market expands Teva’s respiratory portfolio, which allows the company to become a strategic partner of healthcare professionals in treatment of the bronchial asthma of the various grades of severity. I hope that this drug will be available to Russian patients to the same extent as it is available to patients in the USA and other countries.”